Objectives: There is limited information on the use of tigecycline in real-life clinical practice. This analysis aims to identify and understand tigecycline prescribing patterns and associated patient outcomes for approved indications.
Introduction
Tigecycline is a broad-spectrum glycylcycline antibiotic that was approved for use by the US FDA in 2005 and by the European Medicines Agency (EMA) in 2006 for the treatment of complicated skin and soft-tissue infections (cSSTIs) and complicated intra-abdominal infections (cIAIs). 1, 2 In the USA tigecycline is also approved for the treatment of community-acquired bacterial pneumonia. 1 In addition to cSSTIs and cIAIs, short noncomparative studies of the use of tigecycline for non-approved conditions, primarily in severe infections, have also been published. 3, 4 Tigecycline is administered via intravenous infusion at a recommended loading dose of 100 mg, followed by 50 mg every 12 h for 5-14 days, depending on the site and severity of the infection and on the patient's clinical response. 1, 2 Complicated infections can be of polymicrobial origin and are caused by a wide variety of aerobic and anaerobic Gram-positive and Gram-negative bacteria, which may include multiresistant strains. Common organisms associated with cIAIs include bacteria of the family Enterobacteriaceae such as Escherichia coli or Klebsiella spp., staphylococci, streptococci, Pseudomonas aeruginosa, Bacteroides spp., Clostridium spp., Fusobacterium spp., Peptostreptococcus spp. and yeasts, mainly Candida spp.
5 cIAIs are often disseminated infections, characterized by the loss of integrity of the gastrointestinal (GI) tract. Peritonitis may be either a cause of or a consequence of this loss of GI integrity. 5 Most cSSTIs are predominantly caused by the Gram-positive cocci Staphylococcus aureus and Streptococcus species, but E. coli, P. aeruginosa, Enterococcus, Enterobacter and Klebsiella species may also be responsible. 6 There is a wide variation in the aetiology of cSSTIs, and this classification encompasses severe infections that affect the epidermis, dermis and subcutaneous layers. 7 Pharmacological management of these complicated infections presents a challenge, as some of the most common pathogens are often multiresistant, most notably methicillin-resistant S. aureus (MRSA). 8 MRSA is an important nosocomial pathogen, and has been shown to occur in one-third of hospitalized cSSTI patients. 9 Both MRSA and vancomycin-resistant enterococci (VRE) have shown in vitro susceptibility to tigecycline. 10, 11 Moreover, a meta-analysis of eight randomized clinical trials (RCTs) (n¼ 4651) reporting data on microbiologically evaluable patients found tigecycline to be non-inferior to comparator drugs for the treatment of infections caused by MRSA, Streptococcus pneumoniae and Enterococcus faecalis (non-VRE). 12 Empirical treatment of microbial infections involves selecting an agent that has clinically proven efficacy, a low potential for resistance to occur and a low frequency of side effects and drug interactions. In current practice, polymicrobial infections, such as those frequently observed in cIAIs and cSSTIs, are often treated with a combination of antibiotics. Tigecycline, which can be used as monotherapy because of its broad-spectrum coverage, was specifically developed to overcome the mechanisms of microbial resistance. This novel semi-synthetic antibiotic contains a modification to the basic tetracycline structure from which it is derived that preserves its antibacterial activity, 13 and is an approved treatment for infections of polymicrobial origin. 7 The efficacy and safety of tigecycline for the treatment of cSSTIs and cIAIs have been demonstrated in a number of RCTs. 14 -18 In September 2010, the FDA issued a warning regarding an imbalance in overall mortality in patients treated with tigecycline that was noted in the completed clinical trials. 19 A number of meta-analyses have also noted numerically higher all-cause mortality in patients treated with tigecycline versus comparators in RCTs. 12,20 -22 The EMA reviewed the evidence and concluded that the benefits of tigecycline continue to outweigh its risks; however, they issued a recommendation that tigecycline should be used only when it is known or suspected that other antibiotics are not suitable. 23 In real-life clinical practice, many patients with difficult-totreat complicated infections are critically ill, suffer from comorbid conditions and have substantially higher disease severity than those treated with tigecycline in published RCTs. Therefore, the objective of this multinational analysis was to evaluate the clinical use of tigecycline in routine practice as assessed in five noninterventional, observational studies conducted in four European countries [Germany, Italy, France and two studies conducted in Spain (Spain-1 and Spain-2)]. Specifically, the data collected from the respective studies were pooled to describe the tigecycline prescribing patterns in terms of clinical indication, patient demographics and comorbidities, disease severity and therapy regimens (including the concomitant use of other antibiotics) for all patients treated with tigecycline. Response to treatment and mortality were assessed only for patients who received tigecycline alone or in combination with other antibiotics for approved indications (cSSTIs and cIAIs).
Methods

Patients
This analysis included data collected by hospital-based physicians in five non-interventional, observational studies conducted in Europe from July 2006 to October 2011. The study in Germany has been published in full 24, 25 and preliminary data from the studies in Italy, France and Spain-2 have been presented or published. 26 -28 The design of each study and inclusion criteria are described in Table 1 . Data collection on the use of tigecycline was performed prospectively in three multicentre studies in Germany, Spain-1 and France and a single-centre study at the San Martino Hospital in Genoa, Italy. Data collection was performed retrospectively in a multicentre study in Spain-2.
Due to the observational nature of the studies, there were few protocol specifications or inclusion/exclusion criteria ( Table 1) . Hospitalized patients were included if they received tigecycline for any indication during the study period. One study (Spain-1) included only patients who received tigecycline for the treatment of cSSTIs or cIAIs. Two studies (France and Spain-2) included only patients admitted to the intensive care unit (ICU). In all studies, the dosage, duration of treatment and prescription of other antibiotics during or after the start of tigecycline was at the discretion of the physician. All concomitant medications were permitted.
This research was conducted in accordance with the Declaration of Helsinki and all national and institutional standards. The protocol of each study was approved by the local ethics committee or institutional review board. Due to the non-interventional, observational nature of the studies, written informed consent was not required for enrolment in the studies in Germany, Italy and Spain-2. Written informed consent was obtained from patients prior to participation in the studies in France and Spain-1.
Data acquisition and evaluations
Data to be collected were pre-specified in the case-report form with check boxes and included patient age, sex, height, weight, ward of admission, comorbid conditions, infection diagnosis, disease severity score, history of previous antibiotic use (including that prescribed prior to the patient's admission to hospital) and therapy regimens. The severity of disease was evaluated on admission or at the start of tigecycline therapy using the Acute Physiology and Chronic Health Evaluation (APACHE) II score in Germany, Italy, Spain-1 and Spain-2 and by the Sequential Organ Failure Assessment (SOFA) score in France and Spain-2. A history of previous antibiotic use was defined differently in each of the studies and was documented as follows: within 7 days prior to tigecycline use in Germany, within 30 days prior to tigecycline use in France and Italy, at any time during the past year in Spain-1 and within the current hospital or ICU stay in Spain-2.
Prescription characteristics
Dose
The number of patients who were administered the standard dose of tigecycline as specified in the summary of product characteristics 2 and the start and end dates of tigecycline treatment were recorded. a 'Other' includes other 'non-cSSTI and non-cIAI' infections, such as bacteraemia and pneumonia.
Reasons for tigecycline use
A description of the reasons for prescribing tigecycline was collected, using pre-specified reasons in the case-report form with check boxes, including whether it followed on from a previously failed therapy; or if it was given due to a suspicion that the patient might be infected with a resistant strain, prescribed for its broad spectrum of activity, or chosen because of allergy to, or intolerance of, another therapy. Where the reason for tigecycline use was stated as being due to failure of previous therapy, this referred to a lack of efficacy of the first antibiotic that was given in hospital.
Treatment modality and concomitant therapy
The approach used when treating patients with tigecycline was documented for each centre-for example, whether it was used as monotherapy or in combination with other antimicrobial agents. Where tigecycline was used in combination with other agents, the number of patients who were prescribed concomitant therapies and the type of antibiotics were recorded. The number of patients who received the drug as first-or secondline therapy was also recorded in some studies. First-line therapy was considered to be the first treatment that was given to a patient once they had been diagnosed with a complicated bacterial infection.
Clinical outcome
Across the five studies, clinical outcome was assessed by the investigator at the end of treatment (EOT) or upon discharge using the following criteria: 'cure' (complete resolution of infection symptoms; no further antibiotic treatment required), 'improvement' (marked regression of symptoms, no full resolution of infection; however, no further antibiotic therapy required), 'failure' (no relevant decrease in symptoms visible while on treatment with tigecycline) and 'indeterminate' (not assessable for any reason). For this analysis, patients who were assessed by the investigator as 'cured' or 'improved, with no further antibiotic required' at EOT were assigned an outcome of 'response' and patients who were assessed by the investigator as 'failure' or 'improved, with further antibiotic required' were assigned an outcome of 'non-response'. Patients who died following a successful response to tigecycline at EOT were counted as 'responders' and patients who died before or at EOT were counted as 'non-responders'.
Mortality
The number of all-cause deaths that occurred in cSSTI and cIAI patients at any time during the study, including the follow-up period, was recorded in all five studies. The length of the follow-up period varied across the studies and was 1 -3 days after EOT or at discharge in Germany, 30 days after EOT or at discharge in Italy, 12 weeks after study enrolment in Spain-1, 7 days after EOT or at discharge in France and at discharge in Spain-2. A detailed description of the criteria for the assessment of safety is provided in the accompanying paper by Guirao et al.
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Statistical analysis
Descriptive statistics included relative frequencies for categorical variables and means (and standard deviations) or medians (and IQRs) for continuous variables. A pooled analysis of patient-level data was conducted for selected characteristics, including age, sex, body mass index (BMI), disease severity score, presence of comorbidities, history of previous antibiotic therapy, dosage and duration of tigecycline therapy, reasons for tigecycline use and receipt of tigecycline as first-or second-line therapy and as monotherapy or in combination with other antibacterials. Data were analysed in tabulated summaries with the number of patients with available (i.e. non-missing) data as the denominator. Additionally, the denominator used to calculate the occurrence rate of comorbid conditions was the number of patients with ≥1 comorbidity at baseline. Clinical outcome was assessed for cSSTI and cIAI patients who received the standard dose of tigecycline (alone or in combination with other antibacterials) as recommended in the summary of product characteristics.
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Results
Patient population and disease characteristics
Altogether, 1782 patients received at least one dose of tigecycline at 191 sites across the five studies ( Table 1 ). The most frequent indications for which tigecycline was prescribed were cSSTI (254 patients) and cIAI (785 patients), representing 58.3% of the total number of patients treated with tigecycline. Other diagnoses for which physicians used tigecycline included pneumonia, bloodstream infections and sepsis-related conditions. Baseline demographic and disease characteristics are shown in Table 2 . The pooled analysis includes all patients given tigecycline for all indications. Of the total patients, 61.6% were male, with a mean age of 63.4+14.7 (range 15-94) years and a mean BMI of 27.5+6.5 (range 14-90) kg/m 2 . The majority of patients had a history of prior antibacterial therapy (80.2%) and suffered comorbidities (91%). Of 1613 patients who had at least one comorbidity, the comorbidities included hypertension (63.0%), diabetes mellitus (35.4%) and renal insufficiency (33.5%); 21.6% of the patients were obese, 19.2% were smokers and 9.7% had a history of alcohol abuse.
There was wide heterogeneity between the studies in the percentage of patients enrolled from the ICU, with all patients (100.0%) in France and Spain-2 from the ICU compared with 1.7%, 42.6% and 53.2% of patients in Spain-1, Italy and Germany, respectively (Table 2) .
Data on APACHE II scores were collected in four of the five studies, and documented for a total of 1455 patients. Of these, 897 (61.6%) had an APACHE II score .15 at baseline, with the highest proportion (72.7%) in the study from Spain-2 (Table 2 and Figure 1 ). Mean APACHE II scores for patients in Italy, Germany and Spain-2 were 14.9, 18.7 and 19.7, respectively. Among patients who had an APACHE II score of .15, the mean score was 22.3.
SOFA scores were collected for 318 patients in France and Spain-2. Of these, 173 (54.4%) had a SOFA score ≥7 at baseline. Mean SOFA scores for patients in France and Spain-2 were 6.7 and 7.3, respectively ( Table 2 ). Among patients who had a SOFA score of ≥7, the mean score was 10.0.
Prescription characteristics
Dose
Overall, 1591 patients (89.3%) received the standard dosage of tigecycline (100 mg + 50 mg twice daily) as specified in the product label (Table 3) . Mean duration of therapy with tigecycline was 11.1 days (range 1-78 days), with the longest mean duration of tigecycline use recorded in Spain-2 (13.8 days) and the shortest in France (9.9 days).
Reasons for tigecycline use
The main reasons for prescription of tigecycline are shown in Table 4 . Primarily, tigecycline was given because therapy with a previous antibiotic had failed (46.1%), the infection called for a Bassetti et al.
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Treatment modality and concomitant therapy
Tigecycline was used as first-and second-line therapy in 642 (36.3%) and 1127 (63.7%) patients, respectively (Figure 2) . Altogether, 49.6% of patients received other antibacterials in combination with tigecycline; however, differences in monotherapy versus combination prescriptions were observed between countries, with the highest prescription of combination therapy in Spain-2 (84.0%) and the lowest in Italy (24.3%) (Figure 3) . The most commonly used antibacterial classes in combination with tigecycline were the third-and fourth-generation cephalosporins, prescribed to 29.0% of all patients who received concomitant antibacterials and 43.0% of patients in Germany (Table 5) . Within this class, ceftazidime was the most frequently prescribed antibiotic. Aminoglycosides were the class most often prescribed (38.1%) in France. Other antibiotic classes that were commonly prescribed were fluoroquinolones (42.6%) in Spain-1 and carbapenems (27.5%) in Spain-2. Colistin was prescribed in combination with tigecycline in 48.1% of patients in Italy and 30.3% of patients in Spain-2 (Table 5) .
Clinical outcome of cSSTI and cIAI patients
For cSSTI patients who received the standard dose of tigecycline (alone or in combination with another antibacterial), clinical response rates at EOT were 79.6% (183/230) overall, and ranged from 62.5% (10/16) in France (where all of the patients were in the ICU) to 93.8% (15/16) in Spain-1 (where almost none of the patients were in the ICU). For cIAI, the overall response rate was 77.4% (567/733), ranging from 61.6% (45/73) in France to 91.3% (84/92) in Spain-1.
Overall, all-cause mortality (i.e. death that occurred from any cause at any time during the studies, including the follow-up period) was 9.4% (24/254) for cSSTI patients and 18.7% (147/ 785) for cIAI patients, respectively.
Discussion
In this analysis, we investigated how tigecycline was prescribed in real-life clinical practice in five observational studies in four European countries. In particular, we were interested in the type and severity of infections, patient demographic and clinical characteristics, the specific reasons for tigecycline administration and the approach used. The prescription of hospital antibiotics can be challenging due to the widespread threat of multidrugresistant pathogens. Inappropriate use of broad-spectrum antibiotics can facilitate the development of antibiotic resistance. This is especially relevant for some of the Gram-negative opportunistic infections, which can be a cause for concern in the ICU. 30 The management of serious and complicated infections requires expedient treatment with an appropriate antibiotic that has known activity against the causative pathogens. This is particularly challenging in the ICU, where patients require immediate treatment and microbiological culture results are often not available until after an antibiotic has been given. Studies have shown that in patients with cSSTI, healthcare-associated infections and polymicrobial infections are at greater risk of being treated with inappropriate antibiotics, 31 leading to longer length of stay and higher costs. 32, 33 Recent results from a large European multicentre observational study (January to June 2012) that examined outcomes in 2152 patients with intra-abdominal infections reported that patient age, ICU admission, sepsis and septic shock in the post-operative period, and a delayed initial Figure 1 . Disease severity scores at the start of treatment with tigecycline. APACHE II scores were collected in Germany, Italy, Spain-1 and Spain-2, and SOFA scores were collected in France. Percentages were calculated for patients with non-missing data only. The standard dosage of tigecycline is an initial loading dose of 100 mg, followed by 50 mg administered intravenously every 12 h. Only patients who received the standard dose were included.
Bassetti et al.
ii10 intervention (exceeding 24 h) were independent predictors of patient mortality. 34 Furthermore, since a considerable number of patients are under antibiotic treatment once post-operative intra-abdominal infection has been diagnosed, the possible emergence of antibiotic-resistant bacteria should be taken into account when considering focus control and new antibiotic treatment. 35 In this analysis, we describe 1782 patients who received tigecycline under real-life conditions of daily clinical practice. Tigecycline was used to treat a variety of infections, including some for which tigecycline was not granted approval for use. The patients analysed in these observational studies constitute a large and relevant cohort. Most had previously been treated with other antibiotics and suffered from comorbidities. The administration of tigecycline alone or in combination with other antibiotics was solely at the discretion of the physician, and the majority of patients received the standard dosage, with mean treatment duration of 11.1 days. Approximately 58.3% of all patients received tigecycline for an approved indication of cSSTI or cIAI, and half were prescribed tigecycline as monotherapy.
Among the patients treated with concomitant antibiotics, the most common classes prescribed were the third-and fourthgeneration cephalosporins, fluoroquinolones and carbapenems, which may have been given for their antipseudomonal activity. In Germany, ceftazidime was the preferred antibiotic for coverage of P. aeruginosa. Tigecycline appeared to be chosen for its activity against Gram-positive bacteria, and was frequently combined with aminoglycosides in France and with third-or fourth-generation cephalosporins in Germany and Spain-1. The relatively lower rates of concomitant carbapenem prescription in Germany, Spain-1 and France are surprising given that many of these patients had severe infections. It might be speculated that in these cases tigecycline was prescribed as a tool to limit the use of carbapenems. The main reasons for use of tigecycline were its broadspectrum activity (i.e. for treatment of polymicrobial infection), suspicion of resistant pathogens and failure of previous therapy. A high proportion of patients in this analysis had a history of previous antibiotic treatment, and clinical failure of other antibiotics was cited as the reason for prescription of tigecycline in 46.1% of the sample. There was heterogeneity in the documentation of previous antibiotic therapy across the studies. In Germany, the vast majority of patients (84.5%) had received antibiotic therapy within the 7 days before treatment initiation with tigecycline, suggesting that tigecycline may have been administered in many cases as salvage therapy subsequent to failing on the previously chosen antibiotics. Tigecycline is an appropriate choice for patients who have comorbid renal impairment or are undergoing haemodialysis, because no dosage adjustment is needed.
2 Tigecycline was prescribed for this reason in 17.9% of patients in France, but not in Italy or Spain-2. In a few cases, allergy to or intolerance of antibiotics was another reason why the available armamentarium to treat their infection was reduced, necessitating the prescription of an alternative therapeutic agent. This real-life clinical practice is consistent with current international guidelines recommending tigecycline for complicated polymicrobial infections. 36, 37 Susceptibility tests have shown tigecycline to have a broad spectrum of activity against multiple pathogens, including resistant strains that may be present in cSSTIs and cIAIs, such as MRSA, VRE, extended-spectrum-b-lactamase-producing Enterobacteriaceae and carbapenemase-producing Klebsiella pneumoniae, as well as some anaerobes that may be isolated from necrotizing infections. 38 The APACHE II and SOFA scores documented before tigecycline treatment in this patient cohort confirm a particularly high level of disease severity. In those who had an APACHE II score of .15, the mean was 22.3, and in those with a SOFA score of ≥7 the mean was 10.0. Despite the fact that many of these patients were critically ill and requiring ICU care, or had high APACHE II scores at the time of tigecycline administration, the clinical outcomes for patients with cSSTI and cIAI were favourable, and largely in the range of previously reported results in Phase III trials. 14 -18 This analysis did show a range in response rates across the five studies, which probably reflects differences between the various patient populations with regard to disease severity and previous comorbidities, as well as the fact that all patients in the study from France and Spain-2 were in the ICU compared with only 1.7% of the patients in the study from Spain-1.
This analysis has several limitations, and the results should be viewed as descriptive due to the observational, noninterventional and non-comparative design of each study. Furthermore, the data can be complex to interpret, particularly given the heterogeneity of patient populations. The modality of treatment with tigecycline varied across studies: only 24% of patients in Italy received tigecycline in combination with other antibiotics, compared with 84% of patients in Spain-2. This difference might have reflected a difference in the infection characteristics of patients in these countries. Another source of heterogeneity is the fact that the epidemiology of multiresistant pathogens varies across Europe, 39 leading to differences in the clinical approach to treatment. Includes study-level data from Italy.
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These data on European physician prescription behaviour show similarities across the five sites, confirming fairly consistent practices in Germany, Italy, France and Spain with respect to tigecycline, which was primarily used (as approved) for the treatment of cSSTI and cIAI. The results support a robust clinical value of tigecycline in real-life practice for the treatment of complicated infections in critically ill patients.
